TDRD12 Inhibitors
TDRD12 inhibitors belong to a category of chemical agents specifically designed to interact with the TDRD12 protein, a member of the Tudor domain-containing family of proteins. The inhibition of TDRD12 is achieved through the binding of these inhibitors to the protein, thereby affecting its function. The TDRD12 protein typically contains Tudor domains which are known for their role in mediating protein-protein interactions that are essential in various cellular processes. These domains recognize and bind to specific patterns of methylated amino acids, such as those found on histone tails, which helps to regulate the structure of chromatin and influence gene expression. The precise mechanism of how TDRD12 functions within the cell and the pathways it influences can be complex and multifaceted, with its activity impacting the regulation of nucleic acids and involvement in the intricate orchestration of cellular events.
The development of TDRD12 inhibitors is grounded in the science of protein function modulation at the molecular level. By creating molecules that can selectively target and bind to TDRD12, researchers aim to influence the protein's activity. The design of these inhibitors is a sophisticated process that entails understanding the three-dimensional structure of the TDRD12 protein, particularly the configuration of its Tudor domains. The interaction between TDRD12 inhibitors and the protein may involve a range of non-covalent forces, such as hydrogen bonds, hydrophobic interactions, and van der Waals forces. This precise interaction is crucial to ensure that the inhibitor can modulate the function of the TDRD12 protein effectively without affecting other proteins with similar domains or functions, which requires a high degree of specificity in the inhibitor's molecular design.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of PI3K, which is involved in the Akt signaling pathway. Inhibition of PI3K leads to reduced phosphorylation and activation of Akt, thereby potentially reducing the phosphorylation-dependent functions of TDRD12. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MEK inhibitor that interrupts the MAPK/ERK pathway. TDRD12, potentially involved in RNA processing, could be affected by changes in phosphorylation patterns as a result of MAPK/ERK pathway inhibition. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Histone deacetylase inhibitor that alters chromatin structure and gene expression. By changing the transcriptional landscape, it could indirectly affect the expression of TDRD12 by impacting the genes that regulate its expression or stability. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor that can lead to hypomethylation of DNA and affect gene expression. This could impact TDRD12 expression levels by altering the methylation status of its promoter region or that of regulatory genes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor that can disrupt the mTOR signaling pathway, which is crucial for protein synthesis and cell growth. By inhibiting mTOR, the synthesis of TDRD12 could be indirectly affected due to the overall decrease in protein translation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK, which works upstream of ERK in the MAPK pathway. By inhibiting MEK, the phosphorylation and activation of ERK are reduced, which might indirectly affect TDRD12 if it is regulated by ERK-mediated signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A specific inhibitor of p38 MAP kinase, part of the MAPK pathway. Inhibition of p38 MAPK could affect the stress response in cells and potentially downregulate TDRD12 expression if it is implicated in the cellular response to stress. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, another kinase within the MAPK pathway. JNK influences various cellular processes, including apoptosis and transcriptional regulation. TDRD12 could be impacted indirectly if its function or stability is regulated by JNK activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A potent and irreversible inhibitor of PI3K, similar to LY294002, it suppresses Akt signaling. This could lead to a decrease in TDRD12 activity if its function is dependent on Akt-mediated phosphorylation. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $260.00 $925.00 | 5 | |
A selective p300/CBP histone acetyltransferase inhibitor. By inhibiting histone acetylation, C646 can affect gene expression patterns, potentially leading to decreased expression of TDRD12 if it is regulated by acetylation-dependent transcription factors. | ||||||